| Chickenpox
Varizig vs Gamastan
Side-by-side clinical, coverage, and cost comparison for chickenpox.Deep comparison between: Varizig vs Gamastan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGamastan has a higher rate of injection site reactions vs Varizig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gamastan but not Varizig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Varizig
Gamastan
At A Glance
IM injection
Single dose
Varicella-zoster immune globulin
IM injection
Passive immunizing agent
Indications
- Chickenpox
- Hepatitis A
- Measles
- Chickenpox
- Rubella
Dosing
Chickenpox Single weight-based IM dose: 62.5 IU (<=2 kg) to 625 IU (>=40.1 kg); divide into 2 or more injection sites (max 3 mL per site); administer as soon as possible after VZV exposure; consider a second full dose for high-risk patients re-exposed more than 3 weeks after initial administration.
Hepatitis A 0.1 mL/kg within 2 weeks of exposure or for travel stays up to 1 month; 0.2 mL/kg for stays up to 2 months or longer, repeated every 2 months; administer IM.
Measles 0.25 mL/kg IM within 6 days of exposure in susceptible persons; 0.5 mL/kg IM immediately (maximum 15 mL) for immunocompromised children.
Chickenpox 0.6 mL/kg to 1.2 mL/kg IM promptly when Varicella-Zoster Immune Globulin (Human) is unavailable.
Rubella 0.55 mL/kg IM administered only to exposed pregnant women who will not consider therapeutic abortion.
Contraindications
- Anaphylactic or severe systemic hypersensitivity reaction to human immune globulin preparations
- IgA deficiency with antibodies against IgA and a history of hypersensitivity (risk of anaphylactoid reaction)
- Anaphylactic or severe systemic hypersensitivity reactions to Immune Globulin (Human)
- IgA deficiency with antibodies against IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=1%) Injection site pain, headache, rash (including pruritus, rash erythematous, rash vesicular, urticaria), fatigue, chills, nausea
Serious Pyrexia, nausea, vomiting
Most common Fatigue
Postmarketing Anaphylactic reaction, hypersensitivity (rash, flushing, dyspnea), headache, nausea, injection site pain, injection site inflammation, pyrexia
Pharmacology
VARIZIG is a human immune globulin G (IgG) preparation containing antibodies to varicella zoster virus (anti-VZV) that provides passive immunization for non-immune individuals exposed to VZV, reducing the severity of varicella infections.
Polyclonal passive immunizing agent; antibodies in Gamastan neutralize viruses such as hepatitis A and measles to prevent or ameliorate disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Varizig
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Gamastan
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Varizig
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Gamastan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Varizig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Gamastan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Varizig.
Cost estimate not availablePAF Co-Pay Relief: Primary Immunodeficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VarizigView full Varizig profile
GamastanView full Gamastan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.